TP53 mutations as AN independent prognostic factor in 2nd AND FURTHER line THERAPY – EGFR mutated Non-Small Cell Lung Cancer IV PATIENTS treated with Osimertinib

Roeper J, et al. TP53 mutations as AN independent prognostic factor in 2nd AND FURTHER line THERAPY – EGFR mutated Non-Small Cell Lung Cancer IV PATIENTS treated with Osimertinib. Transl Lung Cancer Res 2021 Jan;11(1):4-13. doi: 10.21037/tlcr-21-754

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC

Roeper J, et al. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC. Oncotarget 2020 Jan 21;11(3):250-264. doi: 10.18632/oncotarget.27430